Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Asset Writedowns and Impairment (2023 - 2024)

Neurogene (NGNE) has disclosed Asset Writedowns and Impairment for 1 consecutive years, with $91000.0 as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Asset Writedowns and Impairment changed N/A year-over-year to $91000.0, compared with a TTM value of $91000.0 through Dec 2024, changed N/A, and an annual FY2024 reading of $91000.0, changed N/A over the prior year.
  • Asset Writedowns and Impairment was $91000.0 for Q1 2024 at Neurogene.
  • Across five years, Asset Writedowns and Impairment topped out at $91000.0 in Q1 2024 and bottomed at $91000.0 in Q1 2024.